Jubilant Life Sciences hits 52-week high on USFDA approval for RUBY-FILL

NEW DELHI: Shares of Jubilant Life Sciences rallied nearly 10 per cent in morning trade on Monday to hit a fresh 52-week high of Rs 676.10 on BSE after a unit of its subsidiary received approval from the USFDA .

Jubilant Life Sciences announced to BSE that its wholly own subsidiary Jubilant Pharma, through one of its units Jubilant DraxImage, Montreal, Canada, has received US Food and Drug Administration approval for RUBY-FILL, for its new drug application ( ANDA) pursuant to Section 505 (b)(2) filing.

At 10:00 am, shares of Jubilant Life Sciences were trading 6.4 per cent higher at Rs 654. They hit a low of Rs 653 and a high of Rs 676 in the first 45 minutes of trade.

This approved new drug application provides for the use of RUBY-FILL for positron emission tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease, said the press release.